Allemannsdata Wiki
Manual search

GENETIC ANALYSIS AS

Organization number 993373575 · Aksjeselskap

Programmatic access to company data (JSON)

Source: Firmafakta. Data read and page generated 2026-09-18T20:35:54Z. HTML cache: no-store (TTL 0 seconds). Default TTL for Firmafakta JSON/API responses: 60 seconds.

Facts

Source: Firmafakta, with business data from public registers.

organisasjonsnummer:
993373575
navn:
GENETIC ANALYSIS AS
organisasjonsform:
kode:
AS
beskrivelse:
Aksjeselskap
naeringskode1:
kode:
71.129
beskrivelse:
Annen teknisk konsulentvirksomhet
antallAnsatte:
16
hjemmeside:
www.genetic-analysis.com
epostadresse:
info@genetic-analysis.com
telefon:
48 32 16 10
forretningsadresse:
adresse:
Ulvenveien 80B
poststed:
OSLO
postnummer:
0581
kommune:
OSLO
stiftelsesdato:
2008-09-15
registreringsdatoenhetsregisteret:
2009-01-26
aktivitet:
Utvikle og selge teknologi for analyser av komplekse genetiske, systemer. Salg av varer og tjenester/kompetanse innen analyse.
vedtektsfestetFormaal:
Utvikle og selge teknologi for analyser av komplekse genetiske, systemer.

View the address in Geonorge

Board and other roles

Source: Firmafakta. Also see the separate Brønnøysund lookup under related lookups.

Daglig leder

Regnskapsfører

Revisor

Styre

Owners

Source: Firmafakta shareholder dataset.

Showing top 50 of 221 shareholders by holding size. Raise 'limit' (max 1000) for more.

  1. CITIBANK, N.A. – 24.88 % (9504458 shares, share class: NO0010692130)
  2. AVANZA BANK AB – 16.88 % (6448399 shares, share class: NO0010692130)
  3. MUEN INVEST AS – 4.72 % (1801794 shares, share class: NO0010692130)
  4. S. MUNKHAUGEN AS – 4.58 % (1750116 shares, share class: NO0010692130)
  5. NORDNET BANK AB – 4.41 % (1684196 shares, share class: NO0010692130)
  6. LUCELLUM AS – 4.06 % (1550000 shares, share class: NO0010692130)
  7. SKANDINAVISKA ENSKILDA BANKEN AB – 3.73 % (1423840 shares, share class: NO0010692130)
  8. OCHRINO AS – 3.29 % (1256017 shares, share class: NO0010692130)
  9. LJM AS – 3.1 % (1185202 shares, share class: NO0010692130)
  10. STELLA INVEST AS – 2.77 % (1059232 shares, share class: NO0010692130)
  11. KAGGE AS – 2.62 % (999367 shares, share class: NO0010692130)
  12. TORE GRØTTUM – 1.9 % (726556 shares, share class: NO0010692130)
  13. ERIK BORCH GJONE – 1.79 % (684132 shares, share class: NO0010692130)
  14. MOLVER AS – 1.69 % (644673 shares, share class: NO0010692130)
  15. INVITRODIA AS – 1.52 % (582252 shares, share class: NO0010692130)
  16. JAMA HOLDING AS – 1.12 % (429351 shares, share class: NO0010692130)
  17. BJELLAND CAPITAL I AS – 1.11 % (423077 shares, share class: NO0010692130)
  18. ROLFS HOLDING AS – 1.1 % (420791 shares, share class: NO0010692130)
  19. NORDNET LIVSFORSIKRING AS – 0.73 % (277280 shares, share class: NO0010692130)
  20. PER ANTON INVEST AS – 0.7 % (267910 shares, share class: NO0010692130)
  21. SVENSKA HANDELSBANKEN AB – 0.68 % (261378 shares, share class: NO0010692130)
  22. SAGAHILL AS – 0.68 % (258390 shares, share class: NO0010692130)
  23. LEMICA AS – 0.66 % (253451 shares, share class: NO0010692130)
  24. FROSTAD INVEST AS – 0.6 % (227484 shares, share class: NO0010692130)
  25. OLE ANDREAS BAKSAAS – 0.56 % (212297 shares, share class: NO0010692130)
  26. ARVO INVEST AS – 0.49 % (188723 shares, share class: NO0010692130)
  27. ANNE CAMILLA HUSE BONDESSON – 0.43 % (165042 shares, share class: NO0010692130)
  28. KARLANDER INVEST AS – 0.43 % (163269 shares, share class: NO0010692130)
  29. CHRISTINA WESTBY CASÉN – 0.42 % (160489 shares, share class: NO0010692130)
  30. MARBEL INVEST AS – 0.39 % (149764 shares, share class: NO0010692130)
  31. SKIPS AS TUDOR – 0.35 % (133334 shares, share class: NO0010692130)
  32. E B AAMODT AS – 0.33 % (124409 shares, share class: NO0010692130)
  33. NORDEA BANK ABP – 0.29 % (112587 shares, share class: NO0010692130)
  34. PSEC AB, MALMØ – 0.27 % (102941 shares, share class: NO0010692130)
  35. SKANDINAVISKA ENSKILDA BANKEN AB – 0.26 % (100120 shares, share class: NO0010692130)
  36. FINN ØRJAN RISMYHR SÆLE – 0.26 % (100000 shares, share class: NO0010692130)
  37. BETULUM AS – 0.23 % (87160 shares, share class: NO0010692130)
  38. TOR KRISTIAN STEENSLAND – 0.22 % (83409 shares, share class: NO0010692130)
  39. AMENA AS – 0.22 % (83334 shares, share class: NO0010692130)
  40. SVENSKA HANDELSBANKEN AB – 0.22 % (83200 shares, share class: NO0010692130)
  41. JESEM AS – 0.21 % (80000 shares, share class: NO0010692130)
  42. ISAR INVEST AS – 0.2 % (75758 shares, share class: NO0010692130)
  43. BJØRN ENGER – 0.19 % (73717 shares, share class: NO0010692130)
  44. KARI FURU – 0.19 % (73291 shares, share class: NO0010692130)
  45. THODA INVEST AS – 0.18 % (69356 shares, share class: NO0010692130)
  46. MORTEN LUDWIGSEN – 0.18 % (68779 shares, share class: NO0010692130)
  47. LAKESIDE AS – 0.17 % (64100 shares, share class: NO0010692130)
  48. LARS JOHANSEN TILLER – 0.17 % (63291 shares, share class: NO0010692130)
  49. BRUNO ARMAND MAURICE MAINNEMARD ØIJORDSBAKKEN – 0.15 % (56329 shares, share class: NO0010692130)
  50. RACEINVEST AS – 0.14 % (54150 shares, share class: NO0010692130)

Fetch a longer owner list

Company holdings

Grants and support

Sources provided through Firmafakta: Innovation Norway, the EU, the Research Council of Norway and SkatteFUNN.

Innovasjon Norge (7)

7 results

  1. fylkesnavn:
    Oslo
    kommunenavn:
    Oslo
    org_nr:
    993373575
    bedriftsnavn:
    GENETIC ANALYSIS AS
    virkemiddelkategori:
    Risikolån og garantier
    underkategori:
    Landsdekkende garantier
    innvilget_belop:
    3000000
    innvilget_dato:
    29.01.26
    beslutningsenhet:
    IN Øst
    naringshovedgruppe:
    N - Faglig, vitenskapelig og teknisk tjenesteyting
    naring:
    71.129 Annen teknisk konsulentvirksomhet
    type_finansiering:
    Garanti
  2. fylkesnavn:
    Oslo
    kommunenavn:
    Oslo
    org_nr:
    993373575
    bedriftsnavn:
    GENETIC ANALYSIS AS
    virkemiddelkategori:
    Innovasjonstilskudd
    underkategori:
    Andre innovasjonstilskudd
    innvilget_belop:
    38000
    innvilget_dato:
    23.06.25
    beslutningsenhet:
    IN Øst
    naringshovedgruppe:
    N - Faglig, vitenskapelig og teknisk tjenesteyting
    naring:
    71.129 Annen teknisk konsulentvirksomhet
    type_finansiering:
    Tilskudd
  3. fylkesnavn:
    Oslo
    kommunenavn:
    Oslo
    org_nr:
    993373575
    bedriftsnavn:
    GENETIC ANALYSIS AS
    virkemiddelkategori:
    Risikolån og garantier
    underkategori:
    Landsdekkende risikolån
    innvilget_belop:
    5000000
    innvilget_dato:
    22.06.16
    beslutningsenhet:
    Oslo, Akershus og Østfold DK Styret
    naringshovedgruppe:
    N - Faglig, vitenskapelig og teknisk tjenesteyting
    naring:
    71.129 Annen teknisk konsulentvirksomhet
    type_finansiering:
    Lån
  4. fylkesnavn:
    Oslo
    kommunenavn:
    Oslo
    org_nr:
    993373575
    bedriftsnavn:
    GENETIC ANALYSIS AS
    virkemiddelkategori:
    Innovasjonstilskudd
    underkategori:
    Andre innovasjonstilskudd
    innvilget_belop:
    44100
    innvilget_dato:
    21.03.25
    beslutningsenhet:
    IN Øst
    naringshovedgruppe:
    N - Faglig, vitenskapelig og teknisk tjenesteyting
    naring:
    71.129 Annen teknisk konsulentvirksomhet
    type_finansiering:
    Tilskudd
  5. fylkesnavn:
    Oslo
    kommunenavn:
    Oslo
    org_nr:
    993373575
    bedriftsnavn:
    GENETIC ANALYSIS AS
    virkemiddelkategori:
    Innovasjonstilskudd
    underkategori:
    Andre innovasjonstilskudd
    innvilget_belop:
    31000
    innvilget_dato:
    11.02.26
    beslutningsenhet:
    IN Øst
    naringshovedgruppe:
    N - Faglig, vitenskapelig og teknisk tjenesteyting
    naring:
    71.129 Annen teknisk konsulentvirksomhet
    type_finansiering:
    Tilskudd
  6. fylkesnavn:
    Oslo
    kommunenavn:
    Oslo
    org_nr:
    993373575
    bedriftsnavn:
    GENETIC ANALYSIS AS
    virkemiddelkategori:
    Innovasjonstilskudd
    underkategori:
    Forsknings- og utviklingstilskudd
    innvilget_belop:
    1125000
    innvilget_dato:
    09.12.24
    beslutningsenhet:
    IN Viken
    naringshovedgruppe:
    N - Faglig, vitenskapelig og teknisk tjenesteyting
    naring:
    71.129 Annen teknisk konsulentvirksomhet
    type_finansiering:
    Tilskudd
  7. fylkesnavn:
    Oslo
    kommunenavn:
    Oslo
    org_nr:
    993373575
    bedriftsnavn:
    GENETIC ANALYSIS AS
    virkemiddelkategori:
    Risikolån og garantier
    underkategori:
    Landsdekkende risikolån
    innvilget_belop:
    4400000
    innvilget_dato:
    07.06.24
    beslutningsenhet:
    IN Viken
    naringshovedgruppe:
    N - Faglig, vitenskapelig og teknisk tjenesteyting
    naring:
    71.129 Annen teknisk konsulentvirksomhet
    type_finansiering:
    Lån

EU-tildelinger (0)

No registered grants.

Forskningsrådet (6)

6 results

  1. id:
    64209
    prosjektnummer:
    321516
    prosjekttittel:
    Impact of the SARS-CoV-2 virus in the microbiota and gastrointestinal gut health
    prosjektstart:
    2021
    prosjektslutt:
    2022
    prosjektansvarlig_navn:
    GENETIC ANALYSIS AS
    organisasjonsnummer:
    993373575
    sokt_belop:
    Gasteroenterologi
    tildelt_belop:
    0.0
    virkemiddel:
    Programmer
    aktivitet:
    Brukerstyrte innovasjonsprogrammer
  2. id:
    68018
    prosjektnummer:
    326538
    prosjekttittel:
    Gut microbiota profile recognition in IBD patients
    prosjektstart:
    2021
    prosjektslutt:
    2025
    prosjektansvarlig_navn:
    GENETIC ANALYSIS AS
    organisasjonsnummer:
    993373575
    sokt_belop:
    Gasteroenterologi
    tildelt_belop:
    0.0
    virkemiddel:
    Programmer
    aktivitet:
    Brukerstyrte innovasjonsprogrammer
  3. id:
    60611
    prosjektnummer:
    313879
    prosjekttittel:
    Detection of SARS-CoV-2 in human fecal samples
    prosjektstart:
    2020
    prosjektslutt:
    2023
    prosjektansvarlig_navn:
    GENETIC ANALYSIS AS
    organisasjonsnummer:
    993373575
    sokt_belop:
    Gasteroenterologi
    tildelt_belop:
    0.0
    virkemiddel:
    Programmer
    aktivitet:
    Brukerstyrte innovasjonsprogrammer
  4. id:
    48796
    prosjektnummer:
    283783
    prosjekttittel:
    Liquid Array Diagnostic (LAD) testing of the gut microbiota to determine predictive utility in a clinical setting
    prosjektstart:
    2018
    prosjektslutt:
    2022
    prosjektansvarlig_navn:
    GENETIC ANALYSIS AS
    organisasjonsnummer:
    993373575
    sokt_belop:
    Medisinsk teknologi
    tildelt_belop:
    2.99
    virkemiddel:
    Frittstående prosjekter
    aktivitet:
    Andre frittstående prosjekter
  5. id:
    26044
    prosjektnummer:
    219742
    prosjekttittel:
    Development of an IBD test based on changes in the gut microbiota measured by DNA based GA-map platform
    prosjektstart:
    2012
    prosjektslutt:
    2015
    prosjektansvarlig_navn:
    GENETIC ANALYSIS AS
    organisasjonsnummer:
    993373575
    sokt_belop:
    Bioteknologi
    tildelt_belop:
    0.0
    virkemiddel:
    Programmer
    aktivitet:
    Brukerstyrte innovasjonsprogrammer
  6. id:
    13169
    prosjektnummer:
    192940
    prosjekttittel:
    A gut microbiota analytical platform service
    prosjektstart:
    2009
    prosjektslutt:
    2011
    prosjektansvarlig_navn:
    GENETIC ANALYSIS AS
    organisasjonsnummer:
    993373575
    sokt_belop:
    Bioteknologi
    tildelt_belop:
    0.0
    virkemiddel:
    Programmer
    aktivitet:
    Brukerstyrte innovasjonsprogrammer

SkatteFUNN (16)

16 results

  1. id:
    70968
    innsendt_dato:
    2024-08-27
    prosjektnummer:
    658
    bedriftsnavn:
    GENETIC ANALYSIS AS
    prosjekttittel:
    a) Clostridioides difficile infeksjon - nytt sykdoms område for tarm mikrobiota analyse
    organisasjonsnummer:
    993373575
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    not reported by source
    soknad_godkjent:
    not reported by source
    soknad_avslatt:
    not reported by source
    vedtaksdato:
    na
    prosjekt_fra_ar:
    2024
    prosjekt_til_ar:
    2026
    sammendrag:
    Clostridium difficile infection (CDI) is a disease with symptoms ranging from mild diarrhea to severe life-threatening inflammation of the colon, generally in connection with a severe disturbance of the composition of intestinal microbiota. In the US, CDI is a very common disease, affecting approximately 500,000 patients annually, and of these around 30,000 will die from the disease. Live Biotherapeutic Products (LBP), are new alternative types of therapeutics, intended for the prevention of recurrence of CDI, by restoring the patients’ microbiota to a healthier condition. In this project, Genetic Analysis expertise in the microbiota field will be utilized to develop an easy-to-use, in vitro diagnostic test, by gut bacteria profile recognition, technical and clinical validation, and SW algorithm development. This will provide actionable results to allow for informed decisions regarding disease management and treatment and can be easily accessed by healthcare professionals.
  2. id:
    60115
    innsendt_dato:
    2020-08-31
    prosjektnummer:
    319447
    bedriftsnavn:
    GENETIC ANALYSIS AS
    prosjekttittel:
    Gut microbiota assay development
    organisasjonsnummer:
    993373575
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    NEI
    soknad_avslatt:
    JA
    vedtaksdato:
    2020-09-24
    prosjekt_fra_ar:
    2020
    prosjekt_til_ar:
    2022
    sammendrag:
    Genetic Analysis is a Norwegian biotech company with a dedicated team of scientists with expertise within molecular biology, clinical research and bioinformatics/biostatistics. The company has previously CE-marked and launched the GA-map Dysbiosis test. The test is offered as an IVD version to laboratories in Europe and as "research use only" in the US. Genetic analysis has a production unit producing reagent kits for the Dysbiosis Test as well as an in-house service laboratory facility. The majority of the scientific staff is however working in a dedicated Research and Development team that constantly improves and develops new products for analysis of the human gut microbiota. This project will build on GAs expertise in human microbiota testing. In addition to developing new technological solutions for microbiota testing, GA will in this project explore further the function of viruses in the human gut as well as gaining a better understanding of the interplay between all microorganisms in the human gut (bacteria, viruses and parasites). This will be done by developing and improving novel technologies and methodologies for microbiota assays. GA will also aim to gain novel insight into the causal relationship between microbiota composition and clinical conditions and indications with the ultimate goal of enabling physicians to provide personalized and targeted treatment to patients.
  3. id:
    22332
    innsendt_dato:
    2009-08-20
    prosjektnummer:
    198175
    bedriftsnavn:
    GENETIC ANALYSIS AS
    prosjekttittel:
    Utvikling av GMAP teknologi for analyse av spedbarn og voksen tarmflora
    organisasjonsnummer:
    993373575
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2009-09-15
    prosjekt_fra_ar:
    2009
    prosjekt_til_ar:
    2011
    sammendrag:
    not reported by source
  4. id:
    22334
    innsendt_dato:
    2009-08-20
    prosjektnummer:
    198178
    bedriftsnavn:
    GENETIC ANALYSIS AS
    prosjekttittel:
    Utvikling av GMAP teknologi for det integrative diagnostiske markedet
    organisasjonsnummer:
    993373575
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2009-09-15
    prosjekt_fra_ar:
    2009
    prosjekt_til_ar:
    2011
    sammendrag:
    not reported by source
  5. id:
    70101
    innsendt_dato:
    2024-03-14
    prosjektnummer:
    353237
    bedriftsnavn:
    GENETIC ANALYSIS AS
    prosjekttittel:
    Enhanced method for microbiota analysis
    organisasjonsnummer:
    993373575
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2024-08-30
    prosjekt_fra_ar:
    2024
    prosjekt_til_ar:
    2026
    sammendrag:
    Genetic Analysis (GA) is a Norwegian biotech company. It employs a committed team of scientists specialized in molecular biology, clinical research, and bioinformatics/biostatistics. The company specializes in gut microbiota testing, with GA-map® Dysbiosis Test as its primary product. The test is CE-marked and available as an In Vitro Diagnostic (IVD) product (‘Research Use Only’ in the US). The reagent kits are manufactured in GA’s ISO 13485:2016 certified facilities located in Oslo and distributed to customers worldwide. The Research and Development team is focused on continual improvement of the platform and the creation of novel GA-map® products for analyzing the human gut microbiota.
  6. id:
    61933
    innsendt_dato:
    2021-04-30
    prosjektnummer:
    328402
    bedriftsnavn:
    GENETIC ANALYSIS AS
    prosjekttittel:
    Improved diagnostic tool for microbiota analysis
    organisasjonsnummer:
    993373575
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2021-06-14
    prosjekt_fra_ar:
    2021
    prosjekt_til_ar:
    2023
    sammendrag:
    Genetic Analysis is a Norwegian biotech company with a dedicated team of scientists with expertise within molecular biology, clinical research and bioinformatics/biostatistics. The company has previously CE-marked and launched the GA-map Dysbiosis test. The test is offered as an IVD version to laboratories in Europe and as "research use only" in the US. Genetic analysis has a production unit producing reagent kits for the Dysbiosis Test as well as an in-house service laboratory facility. The majority of the scientific staff is however working in a dedicated Research and Development team that constantly improves and develops new products for analysis of the human gut microbiota. This project will build on GAs expertise in human microbiota testing. In addition to developing new and improved technological solutions for microbiota testing, GA will also aim to gain novel insight into the causal relationship between microbiota composition and clinical conditions and indications with the ultimate goal of enabling physicians to provide personalized and targeted treatment to patients.
  7. id:
    64720
    innsendt_dato:
    2022-04-29
    prosjektnummer:
    337783
    bedriftsnavn:
    GENETIC ANALYSIS AS
    prosjekttittel:
    Preparing development of a Laboratory Developed Test for gut microbiota in the Chinese market
    organisasjonsnummer:
    993373575
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    NEI
    soknad_avslatt:
    JA
    vedtaksdato:
    2022-05-06
    prosjekt_fra_ar:
    2022
    prosjekt_til_ar:
    2023
    sammendrag:
    Several diseases have been linked to changes in the intestinal microbiota composition and function, ranging from gastrointestinal to neurological and autoimmune diseases. Playing a central role in human health, microbiome is today one of the most published topics in gut medical scientific journals. Testing the microbiome is a crucial step toward advancing knowledge in the area, but the lack of easy standardized tests to determine microbiome composition makes it difficult to assess and compare results in research studies. Microbiota also varies across geographies and ethnicities, and research is needed to understand differences in microbiota across populations. Genetic Analysis is a Norwegian science-based diagnostic company and pioneer in the human microbiota field. Our GA-map® platform is based on a pre-determined target multiplex approach specialized for simultaneous analysis of many bacteria in one reaction. The test results are generated by utilizing the patented and clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. Leveraging our experience from successful development and promising growth in European and US markets, we now aim to develop innovative diagnostic solutions for the rapidly growing human microbiota market in China. We have signed a Laboratory Developed Test (LDT) agreement with Thalys Medical Technology Group Corporation, and this project marks the beginning of our collaboration, with necessary steps to prepare for the LDT. This includes establishing a reference lab with the GA technology platform and a healthy reference microbiota profile for the Chinese population. Through this project we will build service opportunities and capabilities essential for Thalys to develop and distribute tests based on our GA-map® technology in China. We will also gain new knowledge about healthy microbiota in the Chinese population, which will be key for further research.
  8. id:
    61923
    innsendt_dato:
    2021-04-30
    prosjektnummer:
    328389
    bedriftsnavn:
    GENETIC ANALYSIS AS
    prosjekttittel:
    Prediction of disease course and treatment escalation in ulcerative colitis through gut microbiota
    organisasjonsnummer:
    993373575
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2021-05-27
    prosjekt_fra_ar:
    2021
    prosjekt_til_ar:
    2024
    sammendrag:
    Genetic Analysis is a Norwegian biotech company with a dedicated team of scientists with expertise within molecular biology, clinical research and bioinformatics/biostatistics. The company has previously CE-marked and launched the GA-map Dysbiosis test. The test is offered as an IVD version to laboratories in Europe and as "research use only" in the US. As of today, there are no solutions able to predict if an individual ulcerative colitis (UC) patient will suffer from mild or severe disease course and finding the appropriate treatment scheme is therefore still an unmet medical need. The intestinal microbiota represents a dynamic environment in which the relative balance of the composition of pro- and anti-inflammatory bacteria species is known to be highly relevant. Mapping of the intestinal microbiota can therefore provide a unique insight to the mechanisms predicting disease course of ulcerative colitis patients, to find the most effective treatment scheme. In this project, Genetic Analysis will develop an easy to use, in vitro diagnostic test that predicts disease course and treatment escalation requirements in patients with ulcerative colitis. Through gut bacteria profile recognition, the test will provide actionable results to allow for informed decisions regarding disease management and treatment. Importantly, the intervention can be used by any molecular diagnostics laboratory, and will therefore be easily accessed by the health care. The development and validation of the test will be done in collaboration with highly experienced clinical partners. This project will build on GAs expertise in human microbiota testing and the overall aim is to provide novel insight into the causal relationship between microbiota composition and clinical conditions and indications. Ultimately this will enable physicians to provide personalized and targeted treatment to patients.
  9. id:
    61934
    innsendt_dato:
    2021-04-30
    prosjektnummer:
    328403
    bedriftsnavn:
    GENETIC ANALYSIS AS
    prosjekttittel:
    Liquid Array Detection
    organisasjonsnummer:
    993373575
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2021-05-26
    prosjekt_fra_ar:
    2021
    prosjekt_til_ar:
    2023
    sammendrag:
    Genetic Analysis is a Norwegian biotech company with a dedicated team of scientists with expertise within molecular biology, clinical research and bioinformatics/biostatistics. The company has previously CE-marked and launched the GA-map Dysbiosis test. The test is offered as an IVD version to laboratories in Europe and as "research use only" in the US. Genetic analysis has a production unit producing reagent kits for the Dysbiosis Test as well as an in-house service laboratory facility. The majority of the scientific staff is however working in a dedicated Research and Development team that constantly improves and develops new products for analysis of the human gut microbiota. There is a need for replacing the explorative hypothesis generating next generation sequencing techniques with techniques that only target microorganisms with diagnostic value. GA will develop a novel technology called Liquid Array Detection that allows detection of complex bacterial communities in a single-tube multiplex reaction, which is both simple and cheap. LAD detection is achieved by combining different channels of fluorescence detection and multiple melting profiles per channel. This project will build on GAs expertise in human microbiota testing and the overall aim is to provide novel insight into the causal relationship between microbiota composition and clinical conditions and indications. Ultimately this will enable physicians to provide personalized and targeted treatment to patients.
  10. id:
    25319
    innsendt_dato:
    2010-09-01
    prosjektnummer:
    206999
    bedriftsnavn:
    GENETIC ANALYSIS AS
    prosjekttittel:
    Utvikling av test for Inflammatorisk tarmsykdom (IBD) basert på GA-map teknologi
    organisasjonsnummer:
    993373575
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2010-12-22
    prosjekt_fra_ar:
    2011
    prosjekt_til_ar:
    2012
    sammendrag:
    not reported by source
  11. id:
    47100
    innsendt_dato:
    2017-09-01
    prosjektnummer:
    279829
    bedriftsnavn:
    GENETIC ANALYSIS AS
    prosjekttittel:
    GA-map platform technology development
    organisasjonsnummer:
    993373575
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2017-11-10
    prosjekt_fra_ar:
    2017
    prosjekt_til_ar:
    2019
    sammendrag:
    not reported by source
  12. id:
    33537
    innsendt_dato:
    2014-08-29
    prosjektnummer:
    242301
    bedriftsnavn:
    GENETIC ANALYSIS AS
    prosjekttittel:
    GA-map(TM) Microarray platform development
    organisasjonsnummer:
    993373575
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2014-10-29
    prosjekt_fra_ar:
    2014
    prosjekt_til_ar:
    2016
    sammendrag:
    not reported by source
  13. id:
    28219
    innsendt_dato:
    2012-08-08
    prosjektnummer:
    223111
    bedriftsnavn:
    GENETIC ANALYSIS AS
    prosjekttittel:
    Utvikling av test for dysbiose av bakterier i tarmen basert på GA-map teknologi
    organisasjonsnummer:
    993373575
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2012-10-25
    prosjekt_fra_ar:
    2012
    prosjekt_til_ar:
    2012
    sammendrag:
    not reported by source
  14. id:
    61139
    innsendt_dato:
    2020-09-30
    prosjektnummer:
    321277
    bedriftsnavn:
    GENETIC ANALYSIS AS
    prosjekttittel:
    Fecal Covid-19 test
    organisasjonsnummer:
    993373575
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2021-01-14
    prosjekt_fra_ar:
    2021
    prosjekt_til_ar:
    2022
    sammendrag:
    Genetic Analysis is a Norwegian biotech company with a dedicated team of scientists with expertise within molecular biology, clinical research and bioinformatics/biostatistics. The company has previously CE-marked and launched the GA-map Dysbiosis test. The test is offered as an IVD version to laboratories in Europe and as "research use only" in the US. Genetic analysis has a production unit producing reagent kits for the Dysbiosis Test as well as an in-house service laboratory facility. The majority of the scientific staff is however working in a dedicated Research and Development team that constantly improves and develops new products for analysis of the human gut microbiota. This project will build on GAs expertise in human microbiota testing. GA will develop and make available a documented diagnostic assay for SARS-CoV-2 in human fecal samples. Further, GA will explore the impact of intestinal SARS-CoV-2 infection on the long-term health of the patient by identifying predictive microbiota profiles that will be integrated with the GA-map Dysbiosis Test. The knowledge generated and products developed in this project will enable physicians to provide personalized and preventive long-term treatment to Covid-19 patients.
  15. id:
    61202
    innsendt_dato:
    2020-10-15
    prosjektnummer:
    321511
    bedriftsnavn:
    GENETIC ANALYSIS AS
    prosjekttittel:
    Improved diagnostic tool for microbiota analysis
    organisasjonsnummer:
    993373575
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    NEI
    soknad_avslatt:
    NEI
    vedtaksdato:
    not reported by source
    prosjekt_fra_ar:
    2020
    prosjekt_til_ar:
    2022
    sammendrag:
    Genetic Analysis is a Norwegian biotech company with a dedicated team of scientists with expertise within molecular biology, clinical research and bioinformatics/biostatistics. The company has previously CE-marked and launched the GA-map Dysbiosis test. The test is offered as an IVD version to laboratories in Europe and as "research use only" in the US. Genetic analysis has a production unit producing reagent kits for the Dysbiosis Test as well as an in-house service laboratory facility. The majority of the scientific staff is however working in a dedicated Research and Development team that constantly improves and develops new products for analysis of the human gut microbiota. This project will build on GAs expertise in human microbiota testing. In addition to developing new and improved technological solutions for microbiota testing, GA will also aim to gain novel insight into the causal relationship between microbiota composition and clinical conditions and indications with the ultimate goal of enabling physicians to provide personalized and targeted treatment to patients.
  16. id:
    67634
    innsendt_dato:
    2023-06-01
    prosjektnummer:
    346253
    bedriftsnavn:
    GENETIC ANALYSIS AS
    prosjekttittel:
    a) Microbiome Health Index – a diagnostic test for gut microbiota monitoring in CDI patients
    organisasjonsnummer:
    993373575
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    not reported by source
    soknad_avslatt:
    not reported by source
    vedtaksdato:
    not reported by source
    prosjekt_fra_ar:
    2023
    prosjekt_til_ar:
    2026
    sammendrag:
    Genetic Analysis is a Norwegian biotech company with a dedicated team of scientists with expertise within molecular biology, clinical research and bioinformatics/biostatistics, in particular within the microbiome field. The company has previously CE-marked and launched the GA-map® Dysbiosis test, a test intended for gut microbiota characterizations. The test is offered as an IVD version to laboratories in Europe and as "research use only" in the US. Clostridium difficile infection (CDI) is a disease with signs and symptoms ranging from mild diarrhea to severe life-threatening inflammation of the colon, generally in connection with a severe disturbance of the composition of intestinal microbiota. In the US Clostridium difficile infection is a very common diseases, affecting approximately 500,000 patients annually, and of these around 30,000 will die from the disease. Live Biotherapeutic Products (LBP), is a new alternative kind of therapeutics, intended for the prevention of recurrence of CDI, by restoring the patients’ microbiota to a healthier condition. An important part in the treatment and restoration process is to identify the need and the effect of the treatment by measuring the baseline status of the microbiota, follow the changes in the microbiota during treatment until finally achieve restoration to a healthier microbiota status. In this project, Genetic Analysis will develop an easy to use, in vitro diagnostic test that through gut bacteria profile recognition will provide actionable results to allow for informed decisions regarding disease management and treatment. Importantly, the intervention can be used by any molecular diagnostics laboratory, and will therefore be easily accessed by the health care. This project will build on GAs expertise in human microbiota testing and the overall aim is to provide novel insight into the causal relationship between microbiota composition and clinical conditions and indications.

Subunits

Open positions

count:
0
stillinger:

No results.

Related lookups

How an AI agent should use this page

Ground rule: Navigate with HTML GET links to keep explanations and relationships. Use the page's JSON alternative only when concrete values must be extracted, compared or computed.

How to use the company page

  1. Use the organization number as the stable key.
  2. Distinguish between the company's own facts, roles, owners, holdings and grants.
  3. Follow person and company links to explore the graph; do not assume relations that are not explicitly registered.

Related services

Time: Ownership, roles and status can change. State the source and retrieval time with factual claims.

AI agent? Read the complete navigation and programming guide.